IntelliPharmaCeutics International (TSXV:IPCI) Scaled Net Operating Assets : -6.36 (As of Aug. 2023)

View and export this data going back to 1999. Start your Free Trial

What is IntelliPharmaCeutics International Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

IntelliPharmaCeutics International's operating assets for the quarter that ended in Aug. 2023 was C$1.57 Mil. IntelliPharmaCeutics International's operating liabilities for the quarter that ended in Aug. 2023 was C$16.48 Mil. IntelliPharmaCeutics International's Total Assets for the quarter that ended in May. 2023 was C$2.35 Mil. Therefore, IntelliPharmaCeutics International's scaled net operating assets (SNOA) for the quarter that ended in Aug. 2023 was -6.36.

IntelliPharmaCeutics International Scaled Net Operating Assets Historical Data

The historical data trend for IntelliPharmaCeutics International's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IntelliPharmaCeutics International Scaled Net Operating Assets Chart

IntelliPharmaCeutics International Annual Data

Trend

Nov13

Nov14

Nov15

Nov16

Nov17

Nov18

Nov19

Nov20

Nov21

Nov22

Scaled Net Operating Assets

Get a 7-Day Free Trial

-0.11

-0.16

-1.15

-1.99

-4.26

IntelliPharmaCeutics International Quarterly Data
	Nov18	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23
Scaled Net Operating Assets	Get a 7-Day Free Trial															-4.39	-6.04	-6.08	-5.61	-6.36

Competitive Comparison of IntelliPharmaCeutics International's Scaled Net Operating Assets

For the Biotechnology subindustry, IntelliPharmaCeutics International's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IntelliPharmaCeutics International's Scaled Net Operating Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IntelliPharmaCeutics International's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where IntelliPharmaCeutics International's Scaled Net Operating Assets falls into.

IntelliPharmaCeutics International Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

IntelliPharmaCeutics International's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Nov. 2022 is calculated as

	Scaled Net Operating Assets (SNOA)		(A: Nov. 2022 )
=	(Operating Assets (A: Nov. 2022 )	-	Operating Liabilities (A: Nov. 2022 ))	/	Total Assets (A: Nov. 2021 )
=	(1.814	-	13.031)	/	2.634
=	-4.26

where

	Operating Assets		(A: Nov. 2022 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	1.927	-	0.113
=	1.814

	Operating Liabilities		(A: Nov. 2022 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	16.161	-	0	-	3.13
=	13.031

IntelliPharmaCeutics International's Scaled Net Operating Assets (SNOA) for the quarter that ended in Aug. 2023 is calculated as

	Scaled Net Operating Assets (SNOA)		(Q: Aug. 2023 )
=	(Operating Assets (Q: Aug. 2023 )	-	Operating Liabilities (Q: Aug. 2023 ))	/	Total Assets (Q: May. 2023 )
=	(1.572	-	16.476)	/	2.345
=	-6.36

where

	Operating Assets		(Q: Aug. 2023 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	2.111	-	0.539
=	1.572

	Operating Liabilities		(Q: Aug. 2023 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	19.465	-	0	-	2.989
=	16.476

IntelliPharmaCeutics International Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of IntelliPharmaCeutics International's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

IntelliPharmaCeutics International (TSXV:IPCI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IntelliPharmaCeutics International Inc (TSXV:IPCI) » Definitions » Scaled Net Operating Assets

Comparable Companies

Traded in Other Exchanges

IPCIF:USA I4AA:Germany

Address

30 Worcester Road, Toronto, ON, CAN, M9W 5X2

Website

https://www.intellipharmaceutics.com

IntelliPharmaCeutics International Inc is a pharmaceutical company. The company is engaged in the research, development, and manufacturing of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its patented Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to the development of a range of existing and new pharmaceuticals. Its ongoing drug development programs are at various stages of development in therapeutic areas that include neurology, cardiovascular, GIT, and pain. The company's product, a generic of Focalin XR, is partnered with Par Pharmaceutical, Inc. and received FDA approval. It derives revenue from the United States.

IntelliPharmaCeutics International (TSXV:IPCI) Headlines

No Headlines